Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.

被引：7
|
作者：
Kelly, Ronan Joseph
Lee, Jeeyun
Bang, Yung-Jue
Almhanna, Khaldoun
Murphy, Mariela A. Blum
Catenacci, Daniel V. T.
Chung, Hyun Cheol
Wainberg, Zev A.
Gibson, Michael
Lee, Keun Wook
Bendell, Johanna C.
Denlinger, Crystal S.
Brohawn, Philip Z.
He, Peng
McDevitt, Jennifer
Englert, Judson
Ku, Geoffrey Yuyat
机构：
[1] Johns Hopkins Med, Baltimore, MD USA
[2] Samsung Med Ctr, Seoul, South Korea
[3] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Seoul, South Korea
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Univ Chicago, Med Comprehens Canc Ctr, Chicago, IL 60637 USA
[7] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[8] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA
[9] Univ Hosp Case, Med Ctr, Cleveland, OH USA
[10] Seoul Natl Univ, Bundang Hosp, Seoul Natl Univ Coll Med, Seoul, South Korea
[11] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[12] Fox Chase Canc Ctr, Philadelphia, PA USA
[13] MedImmune, Gaithersburg, MD USA
[14] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4031
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Safety and activity of durvalumab plus tremelimumab in immunotherapy (IMT)-retreated advanced NSCLC patients.
    Garon, Edward B.
    Spira, Alexander I.
    Goldberg, Sarah B.
    Chaft, Jamie E.
    Papadimitrakopoulou, Vassiliki
    Antonia, Scott Joseph
    Brahmer, Julie R.
    Camidge, D. Ross
    Powderly, John D.
    Wozniak, Antoinette J.
    Felip, Enriqueta
    Gao, Guozhi
    Englert, Judson M.
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma
    Kelley, R.
    Kudo, M.
    Harris, W.
    Ikeda, M.
    Okusaka, T.
    Kang, Y.
    Qin, S.
    Tai, D.
    Lim, H.
    Yau, T.
    Yong, W.
    Cheng, A.
    Gasbarrini, A.
    de Braud, F.
    Bruix, J.
    Borad, M.
    Standifer, N.
    He, P.
    Negro, A.
    Vlahovic, G.
    Sangro, B.
    Abou-Alfa, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S233 - S234
  • [23] Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report
    Mahmood, Syed S.
    Chen, Carol L.
    Shapnik, Natalie
    Krishnan, Udhay
    Singh, Harsimran S.
    Makker, Vicky
    GYNECOLOGIC ONCOLOGY REPORTS, 2018, 25 : 74 - 77
  • [24] Myositis and myocarditis with tremelimumab and durvalumab combination therapy for hepatocellular carcinoma
    Lopez, Thais Lizondo
    Mendez, Iria Carro
    Martin, Esther Carcelero San
    MEDICINA CLINICA, 2024, 162 (07): : 358 - 359
  • [25] T CELL RECEPTOR AND IMMUNE GENE EXPRESSION PHARMACODYNAMICS FOR DURVALUMAB MONOTHERAPY AND IN COMBINATION WITH TREMELIMUMAB OR BEVACIZUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC)
    Kelley, Robin Kate
    Lee, Young
    Conway, James
    Kurland, John
    Negro, Alejandra
    McCoon, Patricia
    HEPATOLOGY, 2024, 80
  • [26] T cell receptor and immune gene expression pharmacodynamics for durvalumab monotherapy and in combination with tremelimumab or bevacizumab in unresectable hepatocellular carcinoma (uHCC)
    Kelley, Robin Kate
    Lee, Young S.
    Conway, James
    Kurland, John F.
    Negro, Alejandra
    McCoon, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Initial treatment efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma in clinical practice
    Tomonari, Tetsu
    Tani, Joji
    Sato, Yasushi
    Tanaka, Hironori
    Morishita, Akihiro
    Okamoto, Koichi
    Kawano, Yutaka
    Sogabe, Masahiro
    Miyamoto, Hiroshi
    Takayama, Tetsuji
    JGH OPEN, 2024, 8 (10):
  • [28] Safety and efficacy of durvalumab (MEDI4736) plus tremelimumab in advanced non-small-cell lung cancer (NSCLC)
    Karakunnel, Joyson J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] Updated efficacy and safety profile of durvalumab monotherapy in urothelial carcinoma
    O'Donnell, Peter
    Massard, Christophe
    Keam, Bhumsuk
    Kim, Sang-We
    Friedlander, Terry
    Ahn, Myung-Ju
    Ong, Michael
    Gordon, Michael
    Butler, Marcus
    Antonia, Scott
    Colon-Otero, Gerardo
    Gutierrez, Martin
    Gupta, Sumati
    Spira, Alexander
    Drakaki, Alexandra
    Maio, Michele
    Xiao, Feng
    Angra, Natasha
    Abdullah, Shaad
    Powles, Thomas
    CANCER RESEARCH, 2018, 78 (13)
  • [30] FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma
    Patel, Timil H.
    Brewer, Jamie R.
    Fan, Jiaxin
    Cheng, Joyce
    Shen, Yuan-Li
    Xiang, Yue
    Zhao, Hong
    Lemery, Steven J.
    Pazdur, Richard
    Kluetz, Paul G.
    Fashoyin-Aje, Lola A.
    CLINICAL CANCER RESEARCH, 2024, 30 (02) : 269 - 273
12345